Soluble programmed cell death-1 predicts hepatocellular carcinoma development during nucleoside analogue treatment.
Soluble programmed cell death-1 predicts hepatocellular carcinoma development during nucleoside analogue treatment.
复制标题
DOI：
10.1038/s41598-021-03706-w
复制
发表时间：
2022-01-07
影响因子：
4.6
通讯作者：
Kawada N
中科院分区：
文献类型：
--
作者：
Kozuka R;Enomoto M;Dong MP;Hai H;Thuy LTT;Odagiri N;Yoshida K;Kotani K;Motoyama H;Kawamura E;Hagihara A;Fujii H;Uchida-Kobayashi S;Tamori A;Kawada N
可溶性免疫检查点分子是一种新型的免疫调节介质。然而，在慢性乙肝病毒感染患者的核糖核酸类似物(NA)治疗过程中，可溶性免疫检查点蛋白是否影响肝细胞癌(HCC)的发展尚不清楚。这项研究包括122名接受NA治疗的天真患者。在NA治疗期间，我们评估了临床因素，包括可溶性免疫检查点蛋白与肝细胞癌发生的相关性。用多重荧光微珠免疫分析法检测16种可溶性免疫检查点蛋白的基线血清浓度。总共有13名患者在随访期内发展为肝细胞癌(中位病程为4.3年)。在16种蛋白中，可溶性诱导型T细胞共刺激因子(≥ 164.71 pg/mL；p = 0.014)、可溶性程序性细胞死亡-1(≤ 447.27 pg/mL；p = 0.031)、可溶性CD40(≤ 493.68 pg/mL；p = 0.032)和可溶性疱疹病毒侵入介质(≤ 2470.83 pg/mL；p = 0.038)与肝癌的发生显著相关(对数等级检验)。在多因素分析中，Spd-1水平 ≤ 为447.27 pg/m L(p = 0.014；风险比[HR]，4.537)和α甲胎蛋白水平 ≥ 6.4 ng/m L(p = 0.040；HR，5.524)与肝细胞癌的发生独立且显著相关。治疗前Spd-1是一种新的预测NA治疗期间肝细胞癌发展的生物标志物。
Soluble immune checkpoint molecules are emerging novel mediators of immune regulation. However, it is unclear whether soluble immune checkpoint proteins affect the development of hepatocellular carcinoma (HCC) during nucleos(t)ide analogue (NA) treatment in patients with chronic hepatitis B virus infection. This study included 122 NA-naïve patients who received NA therapy. We assessed the associations of clinical factors, including soluble immune checkpoint proteins, with HCC development during NA treatment. The baseline serum concentrations of 16 soluble immune checkpoint proteins were measured using multiplexed fluorescent bead-based immunoassay. In total, 13 patients developed HCC during the follow-up period (median duration, 4.3 years). Of the 16 proteins, soluble inducible T-cell co-stimulator (≥ 164.71 pg/mL; p = 0.014), soluble programmed cell death-1 (sPD-1) (≤ 447.27 pg/mL; p = 0.031), soluble CD40 (≤ 493.68 pg/mL; p = 0.032), and soluble herpes virus entry mediator (≤ 2470.83 pg/mL; p = 0.038) were significantly associated with HCC development (log-rank test). In multivariate analysis, an sPD-1 level ≤ 447.27 pg/mL (p = 0.014; hazard ratio [HR], 4.537) and α-fetoprotein level ≥ 6.4 ng/mL (p = 0.040; HR, 5.524) were independently and significantly associated with HCC development. Pre-treatment sPD-1 is a novel predictive biomarker for HCC development during NA treatment.
登录
查看更多内容
影响因子：
6.3
作者：
Liang, Lilian Yan;Wong, Vincent Wai-Sun;Wong, Grace Lai-Hung
通讯作者：
Wong, Grace Lai-Hung
可溶性细胞毒性 T 淋巴细胞抗原 4：治疗后恶性肿瘤的良好预测因子
影响因子：
4
作者：
Liu Q;Hu P;Deng G;Zhang J;Liang N;Xie J;Qiao L;Luo H;Zhang J
通讯作者：
Zhang J
影响因子：
2.5
作者：
Cheung, K. -S.;Seto, W. -K.;Yuen, M. -F.
通讯作者：
Yuen, M. -F.
影响因子：
13.5
作者：
Di Marco, V;Marzano, A;Craxì, A
通讯作者：
Craxì, A
影响因子：
30.5
作者：
Latchman, Y;Wood, CR;Freeman, GJ
通讯作者：
Freeman, GJ